Diseases (AASLD) also presented and continued to revise their clinical practice guidelines,
and the latest updates were in 2015, 2017, and 2018. However, since the medical …

Background Nucleos (t) ide analogues (NUC s) for chronic hepatitis B treatment achieve
high rates of viral suppression and are generally well tolerated. Entecavir (ETV) and …

Hepatitis B virus (HBV) infection remains a global public health problem with changing
epidemiology due to several factors including vaccination policies and migration. This …

Background The novel prodrug tenofovir alafenamide delivers the nucleotide reverse
transcriptase inhibitor tenofovir to target cells more efficiently at a lower dose than tenofovir …

Background & Aims Tenofovir alafenamide (TAF) is a new prodrug of tenofovir developed to
treat patients with chronic hepatitis B virus (HBV) infection at a lower dose than tenofovir …

Background Tenofovir alafenamide is a novel prodrug formulated to deliver the active
metabolite to target cells more efficiently than tenofovir disoproxil fumarate at a lower dose …

Background Treatment with tenofovir disoproxil fumarate has been associated with renal
toxicity or reductions in bone mineral density, or both, in some patients with chronic hepatitis …

Introduction The prevalence of hepatitis B virus (HBV) infection in Australia is nearly 1%. In
certain well defined groups the prevalence is far greater, yet an estimated 27% of people …

Background and Aims Tenofovir amibufenamide (TMF) is a novel phosphoramidated
prodrug of tenofovir with noninferior efficacy and better bone and renal safety to tenofovir …

Methods Chinese hepatitis B e antigen (HBeAg)-positive and-negative chronic hepatitis B
patients with viremia and elevated alanine aminotransferase were randomized 2: 1 to TAF or …